Konferenzen  >  Medizin & Gesundheitswesen  >  Pharmakogenomik, Personalisierte Medizin  >  Kanada

Xtalks

These past few years have marked the acceleration of the adoption of in silico techniques for more efficient and innovative clinical research. When embarking on a new R&D program, scientists face a strategic imperative to assemble the best and most relevant available data and insights. Jinkō, Novadiscovery’s in silico clinical trial simulation platform, has been designed to build and maintain a high-quality knowledge repository, allowing teams to seamlessly cooperate, both internally and with external thought leaders. During the first part of this webinar, featured speaker Dr. Friehs, will explain her role and how she uses jinkō with her fellows to extract, classify and qualify pieces of knowledge in a systematic, transparent and traceable manner, and use these in research reports and literature reviews. After that, featured speaker Frédéric (CPO of Novadiscovery) will showcase how this knowledge is then leveraged directly within jinkō to help lower cost and ethical constraints as well as achieve greater trial efficiency through the design and simulation of in silico trials. This will be illustrated with two practical use cases using Nova’s non-small cell lung cancer (NSCLC) disease model of epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma (LUAD). First, by exploring a large range of doses and then by testing eligibility criteria refinement and its impact on treatment effectiveness. Join this webinar to learn more about using a clinical trial simulation platform to generate auditable and reproducible digital evidence.

Xtalks;     Email: xtalks@dryfta.com

Pharma, Pharmacy

Pharmakologie und Arzneimittelentwicklung,    Legislation in der Medizin und Pharmakologie